Skip to main content

Avalo Therapeutics, Inc.

AVTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001534120

In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.

Q1 2022 vs. Q4 2021

How the institutions holding Avalo Therapeutics, Inc. changed between Q4 2021 and Q1 2022.

All holders in Q1 2022All holders in Q4 2021

13F holders of AVTX: Q4 2021 compared with Q1 2022
MeasureQ4 2021Q1 2022Change
Holders7571−4
Shares80.0M77.7M−2.30M (−2.9%)
Value$136.0M$56.2M−$79.9M (−58.7%)

New holders (10)

Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.

Institutions new to AVTX in Q1 2022
InstitutionSharesValue% of portfolio
BFT Financial Group, LLC62,629$45.0K0.01%
CIBC Private Wealth Group, LLC20,000$14.0K0.00%
Meeder Asset Management Inc17,422$13.0K0.00%
Gyon Technologies Capital Management, LP18,242$13.0K0.01%
Avantax Planning Partners, Inc.12,657$9.00K0.00%
Barclays PLC10,115$7.00K0.00%
Amalgamated Financial Corp.9,807$7.00K0.00%
Brewin Dolphin Ltd9,300$7.00K0.00%
Cubist Systematic Strategies, LLC3,764$3.00K0.00%
FMR LLC249$00.00%

Sold out (14)

Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.

Institutions that sold out of AVTX in Q1 2022
InstitutionShares, Q4 2021Value, Q4 2021
Stonepine Capital Management, LLC1,510,095$2.57M
Soleus Capital Management, L.P.770,000$1.31M
AQR Capital Management LLC91,585$156.0K
Simplex Trading, LLC55,861$94.0K
Virtu Financial LLC33,069$56.0K
LGL Partners, LLC28,850$49.0K
Cambridge Investment Research Advisors, Inc.22,656$39.0K
Voya Investment Management LLC19,776$34.0K
Freestone Capital Holdings, LLC20,000$34.0K
Ethic Inc.20,000$34.0K
XTX Topco Ltd11,685$20.0K
Principal Financial Group Inc10,505$18.0K
ExodusPoint Capital Management, LP10,664$18.0K
SG Americas Securities, LLC10,089$17.0K